CNBC’s “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S.

It's beginning to look a lot like Christmas, but will investors have reason to celebrate? Goldman Sachs and Citadel weigh in.

Morgan Stanley Research increased its 2026 target to $4,400, signaling continued upside through the end of the year. Deutsche ...

Dina Powell McCormick has resigned from Meta Platforms board of directors effective immediately, just eight months after ...

Morgan Stanley is emerging as a leading contender for a key role in SpaceX's blockbuster initial public offering, as the bank ...

Samantha Dart, Goldman Sachs co-head of global commodities research, joins ‘Money Movers’ to discuss the 2026 commodities ...

Texas Instruments has been the group’s largest investor for over 70 years, having donated millions to the United Way’s ...

The fund returned 10.56% in 3Q 2025, outperforming its benchmark as AI and rate cuts supported growth. Review the full ...

Bank of America was among the first to flag a "run-it-hot" scenario for the US economy, defined by robust growth and ...

Access to alternatives is expanding in ways that were almost unthinkable a decade ago. But when it happens this fast, ...

Investing.com -- Goldman Sachs initiated coverage of Technip Energies (EPA:TE) with a “buy” rating, citing strong momentum in ...

Plus: TI begins production at new semiconductor plant in Sherman, Bolt Data & Energy and Texas Pacific Land Corp. agree to ...